Takeda cardiovascular news

Takeda said the Japan Pharmaceutical Manufacturers Association (JPMA) imposed sanctions on the company for promotional activities regarding the investigator-initiated Phase III CASE-J trial of the pharma's Blopress candesartan cilexetil for hypertension. Takeda was suspended for six months from its role as VP of JPMA. Takeda said it takes the sanctions very seriously and sincerely apologizes to all stakeholders. ...